Sato H, Wang Y M, Adachi I, Horikoshi I
Department of Hospital Pharmacy, Toyama Medical and Pharmaceutical University, Japan.
Biol Pharm Bull. 1996 Dec;19(12):1596-601. doi: 10.1248/bpb.19.1596.
This study describes the pharmacokinetic behaviours of taxol after intravenous administration of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate (namely, Taxol-IPM-PLGA-MS) and taxol saline solution to mice. Taxol-IPM-PLGA-MS were prepared using a solvent evaporation technique. The drug content and trapping efficiency of taxol in the microspheres were 5.09% (w/w) and 98%, respectively; the average diameter of the microspheres was 30.1 microns. Scanning electron microscopy showed that Taxol-IPM-PLGA-MS were spherical with a smooth surface. After administration of the drug saline solution (3 mg taxol/kg), taxol disappeared rapidly from plasma within 4-6 h and distributed extensively in various tissues. The tissue levels and AUCfinite of taxol in the lung were obviously higher than those in plasma but relatively lower than those in kidneys, bile, and liver. The biodistribution of taxol after administration of Taxol-IPM-PLGA-MS (3 mg taxol/kg), on the other hand, was altered significantly from the control (taxol solution) group. No taxol was detected in plasma or bile within 3 weeks, and only very low level of taxol was detected in the kidneys or liver within 48 h. However, taxol concentrations in the lung were increased significantly with the microsphere group; the peak concentration of taxol and AUCfinite in the lung was three times and 500 times higher than those with the taxol solution group, respectively. It was also noticed that the taxol levels in the lung were maintained at relatively high levels (> 10 micrograms/ml) for 3 weeks. Thus, the present study demonstrated the effective targeted delivery of taxol to the lung of mice using Taxol-IPM-PLGA-MS.
本研究描述了将含肉豆蔻酸异丙酯的紫杉醇聚(乳酸 - 乙醇酸)微球(即紫杉醇 - IPM - PLGA - MS)和紫杉醇盐溶液静脉注射给小鼠后紫杉醇的药代动力学行为。采用溶剂蒸发技术制备了紫杉醇 - IPM - PLGA - MS。微球中紫杉醇的药物含量和包封率分别为5.09%(w/w)和98%;微球的平均直径为30.1微米。扫描电子显微镜显示紫杉醇 - IPM - PLGA - MS呈球形,表面光滑。给予药物盐溶液(3mg紫杉醇/kg)后,紫杉醇在4 - 6小时内迅速从血浆中消失,并广泛分布于各种组织中。紫杉醇在肺中的组织水平和AUCfinite明显高于血浆,但相对低于肾脏、胆汁和肝脏中的水平。另一方面,给予紫杉醇 - IPM - PLGA - MS(3mg紫杉醇/kg)后,紫杉醇的生物分布与对照组(紫杉醇溶液)相比有显著改变。3周内血浆或胆汁中未检测到紫杉醇,48小时内肾脏或肝脏中仅检测到极低水平的紫杉醇。然而,微球组肺中紫杉醇浓度显著增加;肺中紫杉醇的峰值浓度和AUCfinite分别比紫杉醇溶液组高3倍和500倍。还注意到肺中紫杉醇水平在3周内维持在相对较高水平(>10微克/毫升)。因此,本研究证明了使用紫杉醇 - IPM - PLGA - MS可将紫杉醇有效靶向递送至小鼠肺部。